Global Teduglutide Market Size By Type (Gattex, Revestive), By Application (Hospital, Pharmacy), By Region, And Segment Forecasts, 2023 to 2032

The Global Teduglutide Market was valued at USD 1.1 billion in 2023 and is projected to surpass USD 2.6 billion by 2031, growing at a CAGR of 11.4% during the forecast period from 2023 to 2031. Teduglutide, a glucagon-like peptide-2 (GLP-2) analog, is primarily used for treating Short Bowel Syndrome (SBS). The market is being driven by increasing awareness and diagnosis of SBS, rising demand for effective gastrointestinal treatments, and the expanding patient base resulting from better screening methods and clinical advancements. Moreover, supportive regulatory policies and favorable reimbursement scenarios are further contributing to market growth.

Drivers:

Rising Prevalence of Short Bowel Syndrome:

An increasing number of patients suffering from SBS, particularly due to congenital defects, Crohn’s disease, and post-surgical complications, is significantly driving the demand for teduglutide.

Advancements in Drug Formulations:

Continuous R&D efforts focused on improving teduglutide's efficacy, safety profile, and patient adherence are contributing to the growing adoption of this treatment across key healthcare markets.

Supportive Regulatory and Reimbursement Landscape:

The market benefits from orphan drug designation, expedited approvals, and reimbursement support in key regions like North America and Europe, facilitating wider patient access.

Restraints:

High Cost of Therapy:

Teduglutide therapy is associated with substantial treatment costs, which can limit accessibility, particularly in low-income regions and in healthcare systems with restricted coverage.

Limited Awareness in Developing Regions:

Despite medical advancements, awareness and diagnosis rates of SBS remain low in many developing economies, which may restrict the potential patient pool and adoption rates.

Opportunity:

Market Expansion Through Pediatric Approvals:

The extension of teduglutide usage to pediatric populations presents a significant growth opportunity, supported by ongoing clinical trials and favorable regulatory reviews.

Untapped Markets in Asia-Pacific and Latin America:

Emerging markets present high growth potential due to improving healthcare infrastructure, rising awareness, and increasing investment in rare disease management.

Market by System Type Insights:

By system type, the Injectable Formulation segment held the largest market share in 2023, as teduglutide is currently administered subcutaneously. However, the ongoing development of long-acting and oral analogs may shift dynamics in the forecast period, enhancing patient convenience and adherence.

Market by End-use Insights:

Hospitals and Specialty Clinics dominated the end-use segment in 2023, accounting for over 60% of the market share. These facilities are the primary centers for administering teduglutide, due to their expertise in managing rare gastrointestinal conditions. Homecare settings are expected to gain momentum, particularly in developed countries, driven by the trend toward self-administration and patient convenience.

Market by Regional Insights:

North America led the global teduglutide market in 2023, backed by high SBS diagnosis rates, favorable reimbursement frameworks, and the presence of major pharmaceutical players. Europe followed closely, benefiting from regulatory support for rare disease drugs. Asia-Pacific is expected to witness the fastest growth during the forecast period, owing to rising healthcare investments and increasing SBS awareness.

Competitive Scenario:

Key players in the Global Teduglutide Market include Takeda Pharmaceutical Company Limited (the sole marketer under the brand Gattex/Revestive), Novo Nordisk, Ipsen, Roche, and various clinical-stage biotech firms developing GLP-2 analogs. These companies are focusing on expanding indications, exploring extended-release formulations, and entering strategic collaborations to strengthen their market positioning.

Scope of Work – Global Teduglutide Market

Report Metric Details

Market Size (2023) USD 1.1 billion

Projected Market Size (2031) USD 2.6 billion

CAGR (2023–2031) 11.4%

Market Segments By System Type (Injectable), By End-use (Hospitals, Clinics, Homecare), By Region

Growth Drivers Rising SBS prevalence, drug innovation, reimbursement support

Opportunities Pediatric approval, growth in emerging markets

Key Market Developments:

2023: Takeda received FDA approval for the expanded pediatric use of Gattex (teduglutide) for children aged 1 year and older with SBS.

2024: Clinical trials commenced for long-acting oral GLP-2 analogs aimed at improving compliance and reducing dosing frequency.

2025: A new biosimilar version of teduglutide entered Phase II trials, signaling potential market entry and increased competition in the coming years.

FAQs:

1. What is the current market size of the Global Teduglutide Market?

The Global Teduglutide Market was valued at USD 1.1 billion in 2023.

2. What is the major growth driver of the Global Teduglutide Market?

The major growth driver is the increasing prevalence and diagnosis of Short Bowel Syndrome, along with advancements in GLP-2 analog therapies.

3. Which is the largest region during the forecast period in the Global Teduglutide Market?

North America is the largest region, due to high awareness, diagnosis rates, and favorable reimbursement policies.

4. Which segment accounted for the largest market share in the Global Teduglutide Market?

The Injectable Formulation segment accounted for the largest share, as teduglutide is currently administered via subcutaneous injection.

5. Who are the key market players in the Global Teduglutide Market?

Key players include Takeda Pharmaceutical, Novo Nordisk, Ipsen, Roche, and other biotech companies developing GLP-2 analogs.